Ryan James Hartmaier

机构：AstraZeneca (Netherlands), AstraZeneca (Brazil), AstraZeneca (Japan), AstraZeneca (United States) · ORCID：0000-0001-7416-6036

发表论文 290 篇 · 总被引 6092 次 · h-index 34

代表论文

• Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer (2025 · Nature Medicine · 被引 65)
• ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR -Mutant Advanced Non–Small Cell Lung Cancer Treated with First-Line Osimertinib (2026 · Cancer Discovery · 被引 10)
• Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial (2025 · Clinical Lung Cancer · 被引 6)
• Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO). (2025 · Journal of Clinical Oncology · 被引 4)
• Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non–Small-Cell Lung Cancer in the Absence of Treatment (2025 · JCO Precision Oncology · 被引 3)
• CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer (2026 · Journal of Clinical Oncology · 被引 2)